The present disclosure relates generally to methods and systems for delivering bioadhesive sealants, and more particularly, to methods and systems for delivering bioadhesive sealants in multiple quantities over a period of time.
Various surgical procedures are routinely carried out intravascularly or intraluminally. For example, in the treatment of vascular disease, such as arteriosclerosis, it is a common practice to access the artery and insert an instrument (e.g., a balloon or other type of catheter) to carry out a procedure within the artery. Such procedures usually involve the percutaneous puncture of the artery so that an insertion sheath may be placed in the artery and thereafter instruments (e.g., catheters) may pass through the sheath to an operative position within the artery. Intravascular and intraluminal procedures unavoidably present the problem of stopping the bleeding at the percutaneous puncture after the procedure has been completed and after the instruments (and any insertion sheaths used therewith) have been removed. Bleeding from puncture sites, particularly in the case of femoral arterial punctures, is typically stopped by utilizing vascular closure devices.
While there are a variety of prior art devices and techniques for closing such punctures, one primary problem is insuring a complete seal of the puncture. One technique includes the use of a bioadhesive sealant material to seal the puncture. Some types of bioadhesive sealant materials must be activated prior to use, and should be activated just prior to use in order to avoid premature activation of the bioadhesive sealant material. The handling and activation of bioadhesive sealant materials for use in vascular and other tissue puncture closure applications present a number of challenges, particularly when using bioadhesive sealant components that have a relatively short set time. For example, after a quantity of bioadhesive sealant is delivered through a lumen of a catheter, the bioadhesive sealant may become set within the lumen and prevent additional bioadhesive sealant from being delivered therethrough.
In view of the foregoing, improved systems, devices, and methods for delivering bioadhesive sealants would be desirable. Additionally, systems, devices, and methods for delivering bioadhesive sealants having a relatively short set time, and for delivering bioadhesive sealants in multiple doses, would be desirable.
One aspect of the present disclosure relates to manifolds for the delivery of bioadhesive sealant, which comprise an inlet, a first outlet, a second outlet, and at least one valve positioned and configured to facilitate selective fluid communication between the inlet and the first outlet and the inlet and the second outlet.
The inlet may comprise a first flow path and a second flow path, the first flow path being separate from the second flow path. The first outlet may comprise a first flow path and a second flow path, and the second outlet comprises a first flow path and a second flow path, the first flow path of each of the first and second outlets being positioned for selective fluid communication with the first flow path of the inlet and the second flow path of each of the first and second outlets being positioned for selective fluid communication with the second flow path of the inlet. The first outlet may comprise a mixing chamber in fluid communication with the first and second flow paths of the first outlet, and the second outlet may comprise a mixing chamber in fluid communication with the first and second flow paths of the second outlet.
The inlet may comprise at least one opening sized and configured for coupling to a syringe. The first outlet may comprise an opening sized and configured for coupling to a first lumen of a catheter and the second outlet may comprise an opening sized and configured for coupling to a separate second lumen of the catheter. The valve may comprise a first portion of the manifold, which comprises the inlet, slidable relative to a second portion of the manifold. The second portion of the manifold comprises the first and second outlets. The valve may comprise a first portion of the manifold, which comprises the inlet, rotatable relative to a second portion of the manifold. The second portion of the manifold comprises the first and second outlets.
The valve may comprise a three-way valve positioned between the inlet and the first and second outlets. The three-way valve may comprise a first flow path and a second flow path, the first flow path being configured to selectively provide fluid communication between the first flow path of the inlet and the first flow path of the first outlet, and the first flow path of the inlet and the first flow path of the second outlet. The second flow path may be configured to selectively provide fluid communication between the second flow path of the inlet and the second flow path of the first outlet, and the second flow path of the inlet and the second flow path of the second outlet.
Another aspect of the present disclosure relates to syringes for delivering a bioadhesive sealant, which comprises at least one barrel, at least one plunger, and at least one feature positioned and configured to prevent movement of the at least one plunger relative to the at least one barrel after a first predetermined quantity of bioadhesive sealant has been delivered.
The at least one feature may comprise at least one tab, which provides mechanical interference between the at least one plunger and the at least one barrel when the first predetermined quantity of bioadhesive sealant has been delivered. The at least one tab may be configured to allow the at least one plunger to move relative to the at least one barrel to deliver a second predetermined quantity of bioadhesive sealant upon a force being applied to the at least one tab.
An additional aspect of the present disclosure relates to bioadhesive sealant delivery systems, which comprises a manifold, a syringe, and a catheter. The manifold comprises an inlet, a first outlet, a second outlet, and at least one valve positioned and configured to facilitate selective fluid communication between the inlet and the first outlet and the inlet and the second outlet. The syringe is coupled to the inlet of the manifold, a first lumen of the catheter is coupled to the first outlet of the manifold, and a second lumen of the catheter is coupled to the second outlet of the manifold.
The catheter is configured to deliver a first volume of bioadhesive sealant through the first lumen to a vessel puncture, and deliver a second volume of bioadhesive sealant through the second lumen to the vessel puncture. The catheter comprises an expandable member configured to temporarily seal the vessel puncture. The inlet comprises a first flow path and a second flow path, the first flow path being separate from the second flow path. The first outlet comprises a first flow path and a second flow path and the second outlet comprises a first flow path and a second flow path, the first flow path of each of the first and second outlets positioned for selective fluid communication with the first flow path of the inlet and the second flow path of each of the first and second outlets positioned for selective fluid communication with the second flow path of the inlet. The first outlet comprises a mixing chamber in fluid communication with the first and second flow paths of the first outlet, and the second outlet comprises a mixing chamber in fluid communication with the first and second flow paths of the second outlet.
A further aspect of the present disclosure relates to methods of delivering bioadhesive sealants. Such methods comprise delivering a first quantity of bioadhesive sealant from an inlet of a manifold to a first outlet of the manifold, operating a valve of the manifold, and delivering a second quantity of bioadhesive sealant from the inlet of the manifold to a second outlet of the manifold.
The methods may further comprise delivering the first quantity of bioadhesive sealant from the first outlet of the manifold to a first lumen of a catheter, and delivering the second quantity of bioadhesive sealant from the second outlet of the manifold to a second lumen of the catheter. The methods may further comprise delivering the first quantity of bioadhesive sealant from a syringe to the inlet of the manifold, and delivering the second quantity of bioadhesive sealant from the syringe to the inlet of the manifold. The methods may further comprise depressing at least one tab of the syringe after delivering the first quantity of bioadhesive sealant and before delivering the second quantity of bioadhesive sealant. Operating the valve of the manifold may comprise sliding a first portion of the manifold relative to a second portion of the manifold. Operating the valve of the manifold may comprise rotating a first portion of the manifold relative to a second portion of the manifold.
The foregoing and other features, utilities, and advantages of the invention will be apparent from the following detailed description of the invention with reference to the accompanying drawings.
The accompanying drawings illustrate various embodiments of the present disclosure and are a part of the specification. The illustrated embodiments are merely examples of the present disclosure and do not limit the scope of the invention.
The systems disclosed herein may be used to close or seal percutaneous punctures made through the body tissue of a patient to gain access to a body cavity of a patient. Access through these percutaneous punctures allows a physician to carry out various procedures in or through the body cavity for examination, surgery, treatment and the like. While not meant to be limiting, the systems are illustrated being used to seal percutaneous punctures that provide access to blood vessels in patients for various procedures. It will be appreciated that the systems are applicable to other procedures requiring sealing of a puncture through body tissue into a cavity including, for example, laparoscopic surgery and other microscopic surgery techniques using a relatively small incision.
As used in this specification and the appended claims, the terms “engage” and “engagable” are used broadly to mean interlock, mesh, or contact between two structures or devices. Likewise “disengage” or “disengagable” means to remove or capable of being removed from interlock, mesh, or contact. The words “including” and “having,” as well as their derivatives, as used in the specification, including the claims, have the same meaning as the word “comprising.”
The general structure and function of tissue closure devices used for sealing a tissue puncture in an internal tissue wall accessible through an incision in the skin are well known in the art. Applications of closure devices including those implementing principles described herein include closure of a percutaneous puncture or incision in tissue separating two internal portions of a living body, such as punctures or incisions in blood vessels, ducts or lumens, gall bladders, livers, hearts, etc.
In some embodiments, a bioadhesive sealant delivery system may include a manifold 10 including one or more valves 12, such as shown in
The inlet 14 of the manifold 10 may comprise a first opening to a first fluid flow path 26 and a second opening to a separate second fluid flow path 28. Similarly, each of the first and second outlets 22, 24 of the manifold 10 may include a first opening to a first fluid flow path 30, 32 and a second opening to a separate second fluid path 34, 36. Additionally, the manifold 10 may include at least one valve 12 configured for selectively providing fluid communication between the first fluid flow path 26 of the inlet 14 and one of the first fluid flow path 30 of the first outlet 22 and the first fluid flow path 32 of the second outlet 24. Similarly, the one or more valves 12 of the manifold 10 may be configured to substantially simultaneously selectively provide fluid communication between the second fluid flow path 28 of the inlet 14 and one of the second fluid flow path 34 of the first outlet 22 and the second fluid flow path 36 of the second outlet 24.
In some embodiments, the manifold 10 may comprise a housing 40 and a three-way valve 12. The housing 40 may include the respective fluid flow paths 26, 28, 30, 32, 34, 36 of the inlet 14, the first outlet 22 and the second outlet 24. The three-way valve 12 may be positioned at least partially within the housing 40 and rotatable relative to the housing 40. The three-way valve 12 may include a body 42, a handle 44 coupled to the body 42, a first fluid flow path 46 extending through the body 42, and a separate second fluid flow path 48 extending through the body 42. The housing 40 may include a plurality of visual indicators or stops 50, which may facilitate the positioning of the three-way valve 12 in a first position, as shown in
As shown in
As shown in
In some embodiments, the first and second fluid flow paths 46, 48 within the valve body 42 may each be configured as a single continuous flow path, such as shown in
The syringe 16, shown in
In operation, a prepared syringe 16 may be coupled to a manifold 10, and the manifold 10 (e.g., see embodiment of
As further shown in
Referring to
Referring to
Within a mixing chamber of the first outlet 22, or optionally, upon exiting the first outlet 22, the bioadhesive sealant precursor 18 and the activator 20 may mix together to form an uncured bioadhesive sealant.
Referring again to
Referring to
To deliver the second quantity of bioadhesive sealant to the tract 142, the valve 12 of the manifold 10 may be rotated to the second position. After the first quantity of bioadhesive sealant is delivered, the tabs 52 on the syringe 16 may prevent the further depression of the plungers 54. Accordingly, the tabs 52 may be depressed on the syringe 16 to allow the plungers 54 of the syringe 16 to be further depressed to deliver further bioadhesive sealant precursor 18 from the first barrel of the syringe 16 (see
Within the mixing chamber of the second outlet 24, or optionally, upon exiting the second outlet 24 (see
After delivering the second bioadhesive sealant and forming the second bioadhesive plug 150, the entire vascular closure device 114 and sheath 120 may be removed from the tissue tract 122 and the sealing procedure may be complete.
In additional embodiments, a bioadhesive sealant delivery system 210, such as for sealing a tissue puncture, may include a manifold 212 (e.g., see
The inlet 214 of the manifold 212 may comprise a first opening to a first fluid flow path 230 and a second opening to a separate second fluid flow path 232. Additionally, the manifold 212 may include at least one valve configured to selectively provide fluid communication between the inlet 214 and the first and second outlets 222 and 224.
In one embodiment, as shown in
The first portion 236 of the manifold 212 may include the first flow path 230 and the second flow path 232 of the inlet 214 extending therethrough. The first portion 236 of the manifold 212 may also include openings into the first and second flow paths 230 and 232 of the inlet 214 sized and configured to couple the syringe 216 to the inlet 214. A pivot joint 240, such as one or more of a screw, a pin, a shoulder bolt, and another structure, may join the first portion 236 of the manifold 212 to the second portion 238 of the manifold 212 and facilitate the rotation of the first portion 236 of the manifold 212 relative to the second portion 238 of the manifold 212 about a pivot axis 242.
Each of the first and second outlets 222 and 224 may be located in the second portion 238 of the manifold 212 and may include a first flow path 244, a second flow path 246, a mixing chamber 248 (e.g., a mixing tip), and a third flow path 250. Each of the first flow paths 244 of the first and second outlets 222 and 224 may be positioned and configured for selective alignment with the first flow path 230 of the inlet 214 and the second flow paths 246 of the first and second outlets 222 and 224 may be positioned and configured for selective alignment with the second flow path 232 of the inlet 214. Each mixing chamber 248 may be in fluid communication with the first, second and third flow paths 244, 246, and 250 of the first and second outlets 222 and 224, respectively, and positioned between the third flow path 250 and the first and second flow paths 244 and 246. Each of the third flow paths 250 of the first and second outlets 222 and 224 may extend to a respective opening of the second portion 238 of the manifold 212, which may each be sized and configured to couple to a respective first and second lumen 226, 228 of the catheter.
In operation, a first quantity of bioadhesive sealant may be delivered to the first lumen 226 of the catheter via the first outlet 222 of the manifold 212. To deliver the first quantity of bioadhesive sealant, the syringe 216 may be coupled to the inlet 214 of the manifold, and the first portion 236 of the manifold 212 may be located in the first position (see
Upon exiting the first outlet 222, the bioadhesive sealant precursor and the activator may mix together to form an uncured bioadhesive sealant. The uncured bioadhesive sealant may then be directed through the first lumen 226 of the catheter and into a target site, such as a percutaneous puncture. After a period of time, the uncured bioadhesive sealant may cure, becoming firm. Accordingly, the bioadhesive sealant may provide a bioadhesive plug at the target site. Additionally, the bioadhesive sealant within the first lumen 226 of the catheter may also become firm over the period of time, preventing further uncured bioadhesive sealant from being delivered through the first lumen 226.
To deliver a second quantity of bioadhesive sealant to the target site, the first portion 236 of the manifold 212 may be rotated in the second position (see
Upon exiting the second outlet 224, the bioadhesive sealant precursor 218 and the activator 220 may mix together to form an uncured bioadhesive sealant. The uncured bioadhesive sealant may then be directed through the second lumen 228 of the catheter and into the target site. After a period of time, the uncured bioadhesive sealant may cure, becoming firm. Accordingly, the second quantity of bioadhesive sealant may be provided at the target site, facilitating the use of a bioadhesive sealant having a relatively short curing time.
In an additional embodiment, as shown in
The first portion 336 of the manifold 312 may include a first flow path 330 and a second flow path 332 of the first inlet 314 extending therethrough. The first portion 336 of the manifold 312 may also include openings into the first and second flow paths 330, 332 of the inlet 314 sized and configured to couple one or more syringes 316 to the inlet 314, such as a double barrel syringe 316 comprising a bioadhesive sealant precursor 318 in a first barrel and an activator 320 in a second barrel. A linear slide, such as a dovetail slide, may join the first portion 336 of the manifold 312 to the second portion 338 of the manifold 312 and allow the first portion 336 to move linearly relative to the second portion 338.
Each of the first and second outlets 322, 324 located in the second portion 338 of the manifold 312 may include a first flow path 344, a second flow path 346, a mixing chamber 348 (e.g., a mixing tip), and a third flow path 350. Each of the first flow paths 344 of the first and second outlets 322, 324 may be positioned and configured for selective alignment with the first flow path 330 of the inlet 314, and the second flow paths 346 of the first and second outlets 322, 324 may be positioned and configured for selective alignment with the second flow path 332 of the inlet 314. Each mixing chamber 348 may be in fluid communication with the first, second and third flow paths 344, 346, 350 of the first and second outlets 322, 324, respectively, and positioned between the third flow path 350 and the first and second flow paths 344, 346. Each of the third flow paths 350 of the first and second outlets 322, 324 may extend to a respective opening of the second portion 338 of the manifold 312, which may each be sized and configured to couple a respective first or second lumen 326, 328 of a catheter thereto.
In operation, a first quantity of bioadhesive sealant may be delivered to a first lumen 326 of the catheter via the first outlet 322 of the manifold. To deliver the first quantity of bioadhesive sealant, the syringe 316 may be coupled to the inlet 314 of the manifold 312, and the first portion 336 of the manifold 312 may be located in the first position (see
Within the mixing chamber 348 of the first outlet 322, or optionally, upon exiting the first outlet 322, the bioadhesive sealant precursor 318 and the activator 320 may mix together to form an uncured bioadhesive sealant. The uncured bioadhesive sealant may then be directed through the first lumen 326 of the catheter and into a target site, such as a percutaneous puncture. After a period of time, the uncured bioadhesive sealant may cure, becoming firm. Accordingly, the bioadhesive sealant may provide a bioadhesive plug at the target site. Additionally, the bioadhesive sealant within the first lumen 326 of the catheter may also become cured, preventing further uncured bioadhesive sealant from being delivered through the first lumen 326.
To deliver a second quantity of bioadhesive sealant to the target site, the first portion 336 of the manifold 312 may be slid relative to the second portion 338 of the manifold 312, to the second position (see
Within the mixing chamber of the second outlet, or optionally, upon exiting the second outlet, the bioadhesive sealant precursor and the activator may mix together to form an uncured bioadhesive sealant. The uncured bioadhesive sealant may then be directed through the second lumen 328 of the catheter and into the target site. After a period of time, the uncured bioadhesive sealant may cure, becoming firm. Accordingly, the second quantity of bioadhesive sealant may be provided at the target site, facilitating the use of a bioadhesive sealant having a relatively short curing time.
The sealants discussed herein may comprise a single component, or may comprise multiple sealant components that are mixed together. The multiple sealant components may further react together to form a cross-linked network. The sealant components may be naturally derived or synthetic. Some example synthetic components include polyethers such as polyethylene glycol, polypropylene glycol and polytetrahydrofuran. Other examples of synthetic components may include polyamine compositions such as polyvinylpyrrolidones, polyethylene imines and hydrogenated polyacrylonitriles. Other example sealant components include polyacrylic and methacrylic compounds such as polyacrylic acid. Example naturally derived components include protienaceous compositions such as albumin, collagen and polylysine. Other examples include carbohydrate compositions such polyhyaluronic acid. The sealant components may also contain reactive functional groups to promote chemical cross-linking. The sealant components may be cross-linked by any known method including, for example, condensation reactions, Michael addition, and free radical. Functional groups used for cross-linking may include, for example, thiols, acrylates, amines, succinimydyls and aldehydes, to name a few.
The preceding description has been presented only to illustrate and describe exemplary embodiments of the invention. It is not intended to be exhaustive or to limit the invention to any precise form disclosed. Many modifications and variations are possible in light of the above teaching. It is intended that the scope of the invention be defined by the following claims.
This claims the benefit of U.S. Provisional Application No. 61/726,347, filed 14 Nov. 2012, which is hereby incorporated by reference herein in its entirety.
Number | Date | Country | |
---|---|---|---|
61726347 | Nov 2012 | US |